SYNDAX PHARMACEUTICALS Business Summary

Syndax Pharmaceuticals Inc. (SNDX) is a commercial-stage biopharmaceutical company that generates revenue through a dual-stream model consisting of direct product sales and strategic collaboration agreements. Its primary revenue drivers are Revuforj (revumenib), a first-in-class menin inhibitor fully owned by the company, and Niktimvo (axatilimab), a CSF-1R monoclonal antibody co-commercialized with Incyte, from which Syndax receives 50% of net profits. The company operates within the oncology and fibrotic disease segments, focusing on high-unmet-need indications such as relapsed/refractory acute myeloid leukemia (AML) and chronic graft-versus-host disease (cGVHD). Syndax competes directly with oncology-focused firms like Belite Bio, Arcellx, Kymera Therapeutics, and Cogent Biosciences, positioning itself as a market leader in the menin inhibition space while aggressively expanding its pipeline into frontline AML and idiopathic pulmonary fibrosis. Syndax was co-founded in 2005 by scientific pioneers Peter Ordentlich, Ph.D., Eckard Weber, M.D., and Ronald Evans, Ph.D., leveraging foundational research from the Salk Institute. The current leadership is headed by CEO Michael A. Metzger, a seasoned executive who previously led Regado Biosciences and held senior roles at Forest Laboratories and Mersana Therapeutics. CFO Keith A. Goldan brings nearly 30 years of experience, having previously served as CFO for Optinose and Fibrocell. The executive team is supported by a high-pedigree board chaired by Dennis G. Podlesak and includes notable institutional backing from major investors such as Fidelity Investments, MPM Capital, Avalon Ventures, and Point72 Asset Management.